CML is characterized by the translocation t(9;22)(q34;q11) resulting in the expression of the BCR-ABL fusion protein, which harbours an unrestrained tyrosine kinase activity. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.